Risk Profile Improvements
- Material Weakness (removed) — Two material weaknesses in logical access over accounting software and clinical trial liability reconciliation were disclosed in baseline under active remediation but are absent from current filing with no explanation of resolution status.
MetaVia removes material weakness disclosures; vanoglipel Phase 2a timeline slips one year
Filed May 14, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 14, 2025 · ~1 min read
Key Changes
-
high
Controls section entirely absent from current filing; baseline disclosed two unresolved material weaknesses in accounting software access and clinical trial liability reconciliation, with remediation targeted for 2025.
Controls & Procedures verify on EDGAR → -
high
Vanoglipel (formerly DA-1241) Phase 2a Clinical Study Report and FDA end-of-Phase 2 meeting now expected in first half of 2026, a one-year delay from the original first half 2025 target.
MD&A: Clinical Programs verify on EDGAR → -
high
DA-1726 Phase 1 extended with new Part 3 cohorts testing 48 mg and 64 mg doses via titration protocols; data readout planned Q4 2026, pushing Phase 1 completion beyond original Q4 2025 timeline.
MD&A: DA-1726 Development verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (HOTH 10-Q) is open in full — no account needed.
Partner
Trade MTVA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 10, 2026 9:20 PM